Mechanism of action of DSIP: half-life, cortisol, structure and phospho-DSIP

Delta sleep-inducing peptide (DSIP), also known as emideltide, appears to influence several neuronal and neuroendocrine systems, rather than acting via a single confirmed receptor. Its exact mechanism of action remains unexplained, however, and most data concerning its biological pathways come from animal, tissue or cell studies.

DSIP is a peptide composed of nine amino acids, first identified in experiments involving the cerebral venous blood of rabbits collected in connection with sleep. Its name suggests that it acts as a specific sleep signal. However, subsequent studies have linked DSIP to stress responses, pituitary hormone secretion, circadian activity, GABA and glutamate signalling, monoamines, and processes related to the opioid system. These findings have led to several possible mechanistic explanations, but none of them provides a complete and clinically confirmed picture of DSIP's action in humans [1–4].

Uncertainty goes beyond missing details regarding the mechanism. Researchers have not identified a unique, high-affinity DSIP receptor, a conventional precursor gene clearly responsible for producing the free nonapeptide, or a consistent relationship between a specific blood concentration and a concrete effect in humans. Measurements referred to as „DSIP-like immunoreactivity” may also detect a peptide bound to larger molecules or material with a similar structure, rather than exclusively free, intact DSIP. For this reason, it is important to distinguish between chemical identity, directly measured experimental effects, neuroendocrine observations in humans, and broader mechanistic hypotheses.

How does DSIP work?

The most plausible interpretation suggests that DSIP may act as a context-dependent neuromodulator. A neuromodulator does not have to activate a single receptor and elicit a single predictable response. Instead, it can modify the way neural networks respond to existing inhibitory, excitatory, hormonal and circadian signals. Such an explanation fits the available literature better than describing DSIP as a conventional sleep aid.

In experimental studies, DSIP has been linked to changes in neuronal activity, GABA-activated currents, glutamate and NMDA signalling, monoamine activity, pituitary hormone secretion, stress-related gene expression, and circadian locomotor activity [3–9]. The direction and intensity of these effects often depend on the species, dose, route of administration, time of day, baseline stress level, and the specific brain region or experimental model investigated. Older studies have also described non-linear dose–response relationships or inverted U-shaped curves. In these experiments, an intermediate dose sometimes produced an effect, whereas lower and higher doses did not [3,10].

These observations do not point to a single molecular target. There is no established evidence indicating that DSIP acts as a direct agonist or antagonist of a specific „DSIP receptor”. Claims that DSIP acts exclusively via GABA, serotonin, dopamine, NMDA receptors, cortisol reduction or the opioid system therefore go beyond the available data. Each of these pathways represents an experimental observation or a proposed indirect mechanism, rather than a full explanation of DSIP's action in humans.

Amino acid sequence and molecular structure of DSIP

DSIP is a nonapeptide, which means it consists of nine amino acid residues linked by peptide bonds. The established sequence of the free peptide is:

• H–Trp–Ala–Gly–Gly–Asp–Ala–Ser–Gly–Glu–OH

The single-letter sequence code is:

• WAGGDASGE

The N-terminus starts with tryptophan, whilst the C-terminus ends with glutamic acid. Serine is located at position 7 and is particularly important in the case of phospho-DSIP, as its hydroxyl side chain can undergo phosphorylation. Primary sequence studies also showed that structural details can influence activity. Synthetic DSIP increased delta and sleep spindle activity in the EEG of a rabbit model, whereas the tested fragments, analogues with a modified sequence, and the beta-aspartyl isomer showed lower activity or remained inactive under the same experimental conditions [1]. This demonstrates the structure-activity relationship in the initial animal study, but does not confirm the existence of a specific human DSIP receptor.

For unmodified free DSIP, the PubChem database gives the molecular formula C35H48N10O15, an approximate molecular mass of 848.8 g/mol, and PubChem Compound ID 68816 [14]. CAS number 62568-57-4 is commonly assigned to emideltide or free DSIP. However, a CAS number, a chemical database identifier or an international nonproprietary name only identify a specific chemical substance. They do not confirm regulatory approval, clinical efficacy, purity or equivalence between free DSIP and its salt form.

Text-based structure diagram

The structure of the DSIP peptide can be presented without suggesting that it possesses a single, fixed, biologically active three-dimensional conformation:

A flat sequence diagram is more scientifically appropriate than presenting a single polished „molecular model” as the biologically active shape of DSIP. Short peptides exist in solution as dynamic ensembles of various conformations. Their conformational behaviour can change depending on pH, ionic strength, solvent, membranes, binding partners, phosphorylation and concentration. No definitive structure of receptor-bound DSIP has been established that confirms a single active three-dimensional conformation.

The quoted molecular mass also requires appropriate context. The value of approximately 848.8 g/mol refers to the neutral, unmodified peptide represented by the formula C35H48N10O15. Acetate salts, hydrated forms, counter-ions, phosphorylation, isotopic labels and other modifications can alter the molecular formula or the measured molecular mass. The quantity in milligrams stated on a commercial vial does not confirm the exact chemical form or the amount of the intact, active peptide present within it.

Proposed neuronal and neuroendocrine mechanisms

Research into DSIP spans several levels of biological organisation, from electrical responses in isolated neurones to stress reactions in whole animals. These different levels should not be combined into a single pathway. An electrophysiological experiment may show that DSIP modifies neuronal responses under controlled conditions, but it cannot on its own confirm that the same mechanism induces sleep, lowers cortisol or improves clinical status.

One of the main areas of mechanistic research concerns the balance between inhibitory and excitatory signalling. In rat hippocampal and cerebellar neurones, DSIP dose-dependently enhanced currents activated by GABA, the main inhibitory neurotransmitter in the brain. In cortical and hippocampal preparations, DSIP also blocked NMDA-activated potentiation. Experiments using cerebral cortex synaptosomes further suggested modulation of presynaptic NMDA-associated calcium uptake [6]. In separate experiments on rat neurones, it was found that DSIP reduced the excitatory effects induced by glutamate [7]. Taken together, these results support the possibility of a shift towards lower neuronal excitability. However, they do not demonstrate that DSIP binds directly to GABA-A or NMDA receptors at concentrations achievable in humans.

Research into seizures and stress in animals is generally consistent with this balance model between inhibition and excitation. During increased oxygen pressure, the administration of DSIP to rats was associated with higher concentrations of GABA and homocarnosine in the cerebral cortex and lower concentrations of glutamate and aspartate [15]. This was a biochemical finding originating from a specialised animal seizure model. It cannot be directly translated into claims that DSIP is a GABAergic drug, an NMDA antagonist, or an anticonvulsant for humans.

Monoaminergic mechanisms were also investigated. In a thermoregulation experiment in rats, the effect of DSIP on temperature changes induced by a serotonin agonist was modified by pharmacological blockade. Researchers therefore suggested the possible involvement of a mechanism related to the 5-HT1A receptor [8]. DSIP and phosphorylated DSIP also altered apomorphine-induced hypothermia, whereas haloperidol antagonised both effects. This suggested a link with dopaminergic signalling in this specific thermoregulatory model [9]. These studies demonstrate the dependence of specific animal responses on particular pathways, but do not confirm that DSIP is a serotonin or dopamine receptor agonist.

The endogenous biology of DSIP remains particularly obscure. DSIP-like immunoreactivity has been detected in the brain, pituitary gland, peripheral tissues, plasma, cerebrospinal fluid, urine and milk. Some of this immunoreactive material appears to be bound to larger molecules. Antibody-based methods do not always distinguish between intact free DSIP and bound peptide, precursor-like material or cross-reacting sequences. Reviews of DSIP have therefore described it as an incompletely understood peptide system rather than a fully characterised hormone with a defined gene, receptor, synthesis pathway and feedback mechanism [2–4].

DSIP, ACTH and cortisol

DSIP has been studied as a potential regulator of the hypothalamus–pituitary–adrenal axis, commonly referred to as the HPA axis. In the classical stress response pathway, the hypothalamus releases corticotrophin-releasing hormone (CRH). CRH stimulates the pituitary gland to secrete adrenocorticotropic hormone (ACTH), and ACTH then stimulates the adrenal cortex to produce cortisol in humans or mainly corticosterone in rats. DSIP-related results have been observed at several stages of this system, but they do not confirm that DSIP is a substance that reliably lowers cortisol levels.

A small clinical experiment investigated ACTH and arginine vasopressin responses in healthy men. DSIP was administered by infusion to eight participants during one part of the protocol, whereas another seven participants were included under different time conditions. DSIP significantly reduced blood ACTH concentrations, but did not affect baseline vasopressin concentrations or its response to osmotic and orthostatic stimuli [11]. This is direct neuroendocrine evidence derived from a human study. However, the experiment was small and physiological in nature. It did not demonstrate a therapeutic effect on cortisol, long-term benefits, clinical efficacy or the safety of contemporary subcutaneous or intranasal DSIP products.

In another human study, the CRH stimulation test was used in 12 individuals with major depressive disorder and 12 matched control subjects. Baseline DSIP and cortisol concentrations were correlated with each other and higher in the participants with depression. DSIP responses following CRH administration also differed between the two groups. The researchers considered these results to be consistent with a possible modulating role of DSIP in the regulation of the HPA axis [12]. However, because this was a biomarker and response-to-stimulus study, it does not demonstrate that administering DSIP lowers cortisol levels or treats depression.

Data from animals are similarly dependent on experimental conditions. In rats subjected to prolonged immobilisation stress, levels of ACTH, corticosterone and beta-endorphin increased. Administration of DSIP partially reduced the increase in corticosterone, but did not lead to a simple inhibition of all measured hormones [13]. Other experiments suggested that the neuronal effects of DSIP depended on baseline corticosteroid concentrations and became more apparent under stress-related conditions. Such a pattern is more consistent with state-dependent modulation than with a universal cortisol inhibition mechanism.

For this reason, the statement „DSIP lowers cortisol” is too categorical. A more precise conclusion is that limited data from human and animal studies suggest an interaction of DSIP with HPA axis regulation, including ACTH and corticosteroid responses, but there is no validated clinical protocol demonstrating a predictable reduction in cortisol. Cortisol is also subject to a strong circadian rhythm and depends on illnesses, sleep deprivation, food intake, physical activity, medications, and sampling conditions. A single cortisol measurement therefore requires appropriate context.

DSIP and sleep-regulating pathways

DSIP derived its name from the observed experimental phenotype rather than the discovery of a specific receptor pathway. Initial experiments on rabbits utilised material collected during electrically induced sleep and demonstrated that the isolated and subsequently synthesised nonapeptide increased delta activity and sleep spindles on the EEG following intracerebroventricular administration [1]. Subsequent experiments yielded mixed results depending on the species, route of administration, dose and treatment schedule. This inconsistency is one of the reasons why the proposed role of DSIP as a universal endogenous sleep factor remains a subject of debate [2–4].

Several mechanisms could potentially link DSIP with the regulation of sleep. An increase in GABA-related inhibition combined with a decrease in glutamate- and NMDA-related excitation could restrict neuronal excitation in certain circuits [6,7]. Changes in serotonergic and dopaminergic activity could influence sleep-wake transitions, thermoregulation and circadian behaviours [8–10]. Modulation of the HPA axis could indirectly affect sleep under conditions of increased stress system activity [11–13]. However, none of these pathways has been established as the primary mechanism responsible for the reproducible effects of DSIP on human sleep.

Animal studies also suggest that the timing of administration and the exposure pattern may influence the response. Repeated administration altered circadian locomotor activity under continuous lighting conditions, with native DSIP and P-DSIP eliciting different patterns [10]. In rat sleep studies, the phosphorylated analogue increased both slow-wave sleep and paradoxical sleep following central administration, although the effective dose range was non-linear [16,17]. These results may help in generating hypotheses regarding circadian regulation and sleep architecture, but they do not prove that peripheral administration in humans leads to reaching the same brain areas or produces the same effects.

Human insomnia studies have not consistently shown strong effects. Some small experiments have noted changes in sleep-related parameters, but controlled studies have generally shown weak, variable or clinically limited benefits. Therefore, even if DSIP modifies neuronal pathways associated with inhibition, stress or circadian rhythm, mechanistic findings have not translated into an established insomnia treatment.

What is known about the half-life of DSIP?

A well-established elimination half-life of DSIP in humans, which would allow for the reliable determination of clinical duration of action, accumulation, or dosing frequency, has not been established.

The frequently cited value of approximately 15 minutes originates from proteolytic degradation experiments conducted on brain slices or homogenates. In these experiments, the measured endpoint was the removal of the N-terminal tryptophan [3]. This is a measurement of degradation in tissue in vitro, rather than a contemporary measurement of the pharmacokinetic half-life following intravenous administration in humans.

Previous studies using rat brain homogenates show the same difference. After 7.5 minutes’ incubation with 2.5% brain homogenate, approximately 30% of N-terminal tryptophan DSIP was released. The rate of degradation varied depending on experimental conditions and developmental age [5]. This type of test demonstrates susceptibility to enzymatic cleavage. It does not directly measure absorption, distribution, plasma clearance, tissue binding, renal excretion or duration of action in a living human organism.

Incubation studies with blood similarly showed that DSIP degradation was dependent on time, temperature and species. Native DSIP disappeared relatively quickly in human or rat blood preparations, forming products consistent with the removal of the N-terminal tryptophan. Phosphorylated or N-terminally modified labelled analogues degraded more slowly and formed complexes or aggregates that could potentially prolong the apparent presence of intact material [18]. These were biostability studies rather than validated pharmacokinetic studies in humans.

This difference explains why the terms „half-life” and „duration of effect” should not be used interchangeably. A peptide may rapidly disappear from the free circulating plasma fraction while simultaneously triggering downstream signalling that persists for much longer. On the other hand, immunoreactive material may remain detectable because it is bound to a carrier or because the assay includes related fragments, even though they are not biologically equivalent to intact free DSIP.

Published data do not provide reliable values regarding the terminal half-life, bioavailability, volume of distribution, clearance or human exposure following intranasal or subcutaneous administration.

Metabolism, degradation and pharmacokinetic uncertainty

N-terminal tryptophan appears to represent an important early cleavage site in several DSIP degradation experiments. Peptidases present in tissues and blood can sequentially remove residues or cleave peptide bonds, generating fragments that may be inactive, exhibit altered activity or remain detectable by specific analytical methods. The measured degradation rate can be influenced by temperature, pH, enzyme concentration, species, biological matrix and peptide modification [3,5,18].

Protein binding and aggregation further complicate interpretation. Earlier studies suggested that endogenous DSIP-like immunoreactivity may be associated with larger carrier proteins, potentially protecting the peptide from rapid proteolytic degradation [3]. Modified analogues also demonstrated complex formation and slower degradation in vitro [18]. As a result, an assay measuring total immunoreactivity may yield a different result than an analytical method measuring specifically intact, free DSIP.

Animal studies and in vitro endothelial cell model research on the blood-brain barrier have suggested a certain degree of DSIP penetration. However, the transport results do not determine what proportion of a contemporary nasal or injectable product reaches neuronal targets in humans. Route-dependent absorption, mucosal metabolism, peripheral binding, renal elimination, and local tissue degradation remain insufficiently characterised. Claims that nasal DSIP completely „bypasses” degradation or delivers a specific fraction of the substance directly to the brain are not supported by adequate pharmacokinetic studies.

These pharmacokinetic uncertainties also prevent scientifically reliable conversion of exposure between intravenous, subcutaneous, intranasal and oral administration. Identical amounts given via different routes do not necessarily lead to equivalent blood concentrations or brain exposure. The literature therefore does not allow justification of a clinical dosing schedule based on the approximately 15-minute degradation observed in vitro.

What is phospho-DSIP or P-DSIP?

Phospho-DSIP, also known as P-DSIP or DSIP-P, is a phosphorylated form of DSIP in which the serine residue at position 7 contains a phosphate group.

Phosphorylation introduces an additional negatively charged chemical group and can alter the conformation of the peptide, its susceptibility to enzymes, binding properties, aggregation, and biological behaviour. P-DSIP should therefore not be treated simply as another name for native DSIP.

Immunochemical assays identified a DSIP-like phosphorylated form at Ser7. An in vitro enzymatic experiment also demonstrated that casein kinase II can phosphorylate DSIP, using ATP or GTP as a phosphate donor. Under these conditions, the apparent substrate affinity was low, and the researchers described DSIP as a potential in vitro substrate without identifying the enzyme responsible for phosphorylation in a living human organism [19]. Demonstrating that an enzyme can phosphorylate DSIP in a laboratory system does not prove that the same reaction constitutes its natural biosynthetic pathway in the human body.

Phosphorylation also changes the molecular mass. The addition of a phosphate group increases the mass of the peptide by approximately 80 Da. The expected molecular mass of singly phosphorylated P-DSIP is therefore approximately 928.8 Da, depending on the ionisation and salt form. This is a calculated chemical value, not an analytical result for a specific batch of product.

Native DSIP versus phosphorylated analogues

Native DSIP and P-DSIP behaved differently in animal studies and in vitro experiments.

In freely moving rats, a continuous, ten-hour nocturnal intraventricular infusion of 0.5 nmol P-DSIP increased slow-wave sleep by 22% and REM sleep by 81%. The increase was due to a greater number of sleep episodes, whilst both higher and lower doses tested were ineffective. In this particular experiment, the researchers estimated that P-DSIP was approximately five times more potent than native DSIP [16].

In another experiment on rats, P-DSIP was administered into the third ventricle prior to the dark period. At a dose of 200 pmol/kg, P-DSIP increased slow-wave sleep by 17.3% and paradoxical sleep by 32.3% during the dark period following administration, without shortening sleep latency. The effect on slow-wave sleep persisted into the subsequent light period, after which the values returned to control levels on the second day [17]. These were animal studies utilising central administration. These were not human studies and do not establish a protocol for intranasal or subcutaneous administration.

P-DSIP also did not behave as a consistently longer-acting form in all experimental models. In the experiment concerning apomorphine-induced hypothermia, the effect of P-DSIP appeared and disappeared faster than the effect of native DSIP [9]. In contrast, in blood incubation studies, labelled phosphorylated analogues showed slower degradation and complex formation [18].

These seemingly disparate results show why the duration of the effect depends on what exactly is being measured. Chemical stability in a biological matrix, receptor-related physiology, behaviour and sleep architecture may operate on different timescales.

Which statements regarding the mechanism are confirmed, and which are hypothetical?

Among the best-confirmed chemical findings are the nine-amino-acid sequence of DSIP, the approximate molecular formula and mass of the free peptide, and the location of the Ser7 phosphorylation site [1,14,19].

Experimental data also show that DSIP may undergo degradation in brain and blood preparations, P-DSIP may behave differently than native DSIP, and DSIP may modify parameters related to GABA, glutamate, NMDA, monoamines and the neuroendocrine system in selected experimental models [5–13,16–19].

Equally important are the areas of uncertainty.

No unique DSIP receptor has been established. No single intracellular signalling pathway explains all reported effects of DSIP. The frequently cited value of 15 minutes is not an established elimination half-life in humans. No predictable cortisol-lowering action has been demonstrated. It is also unknown whether the observed effects on GABA or NMDA explain sleep responses in humans.

Similarly, greater P-DSIP activity in selected animal experiments does not confirm its superiority in humans. The detection of DSIP-like immunoreactivity also does not necessarily indicate the concentration of intact, free DSIP.

Data limitations regarding the mechanism of action

A significant portion of the literature concerning DSIP dates from the 1970s to the 1990s. Many of these experiments utilised methods designed to answer much narrower questions than modern receptor pharmacology, proteomics, mass spectrometry-based pharmacokinetics or controlled clinical trials.

Numerous results rely on intracerebroventricular administration, isolated neurones, tissue homogenates, synaptosomes, radioimmunoassays or specialised animal models related to stress and thermoregulation.

Results also vary depending on the species, route of administration, dose, duration, and initial physiological state. Non-linear dose–response relationships particularly hinder broad extrapolation.

Antibody-based measurements of DSIP-like material may also fail to consistently distinguish between the intact free peptide, larger bound forms and cross-reacting molecules.

Mechanistic findings therefore remain valuable for the generation and testing of research hypotheses, but cannot establish an effective human dose, treatment schedule, clinical benefit, or safety profile.

Frequently asked questions about the DSIP mechanism

What is the mechanism of action of DSIP?

DSIP appears to affect inhibitory, excitatory, monoaminergic, circadian and HPA axis-related processes, but a single receptor or uniform mechanism of action has not been confirmed.

The most direct pathway data come from animal neuron and tissue studies and small neuroendocrine studies, rather than definitive human receptor studies.

How does the DSIP peptide affect sleep?

Potential sleep-related mechanisms include enhancement of GABA-related inhibition, limitation of glutamate- and NMDA-related excitation, changes in monoaminergic signalling, circadian rhythm modulation, and alterations in stress axis activity under specific conditions [6–13].

None of these mechanisms has been established as the primary pathway responsible for the effects on sleep in humans, and clinical results regarding sleep have been inconsistent.

Does DSIP bind to GABA receptors?

DSIP enhanced GABA-activated currents in rat hippocampal and cerebellar neurones [6].

However, this result does not prove that DSIP binds directly to a specific GABA receptor site. Neither does it confirm that DSIP acts like benzodiazepines or other GABAergic drugs.

Does DSIP affect glutamate or NMDA receptors?

Experiments on rat neurones and synaptosomes have shown changes concerning glutamate-dependent excitation, NMDA-associated potentiation and calcium uptake [6,7].

These preclinical observations support the possibility of modulating excitatory signalling, but do not confirm a clinically useful NMDA-blocking effect in humans.

Does DSIP lower cortisol levels?

Not predictably on the basis of current evidence.

Small human trials and animal stress experiments suggest that DSIP may influence the regulation of ACTH, cortisol or corticosterone. However, these studies do not support DSIP as a reliable method for lowering cortisol levels [11–13].

What is the half-life of the DSIP peptide?

A validated half-life of DSIP in human plasma has not been established.

The frequently cited value of about 15 minutes comes from studies of the proteolytic removal of tryptophan in brain slices or homogenates, rather than from measurements of the pharmacokinetic elimination of DSIP in humans [3].

Why might the action of DSIP last longer than its degradation time?

A peptide can trigger further neuronal or hormonal processes that persist after the degradation or removal of the original molecule.

Binding to larger molecules, tissue distribution, assay cross-reactivity and the presence of detectable or biologically active fragments may also cause differences between measured DSIP-like immunoreactivity and the actual concentration of intact free DSIP.

What is the molecular mass of DSIP?

The unmodified free peptide has an approximate molecular mass of 848.8 g/mol and a molecular formula of C35H48N10O15 [14].

Salt forms, counterions, hydration, isotopic labelling or phosphorylation can alter the molecular formula or measured mass.

What is the CAS number of DSIP?

CAS number 62568-57-4 is commonly assigned to emideltide or free DSIP.

Catalogue information should, however, be checked for the exact chemical form, as the free peptide, acetate forms, modified analogues and analytical standards are not automatically equivalent.

What is the amino acid sequence of DSIP?

The DSIP sequence is Trp–Ala–Gly–Gly–Asp–Ala–Ser–Gly–Glu, abbreviated as WAGGDASGE [1].

This is a nonapeptide containing serine at position 7.

What is phospho-DSIP?

Phospho-DSIP, P-DSIP or DSIP-P is a form of DSIP phosphorylated at Ser7.

In selected in vitro and animal studies, differences were observed between P-DSIP and native DSIP in terms of degradation, thermoregulation, circadian activity, and sleep-related effects [9,10,16–19].

Is P-DSIP better than native DSIP?

This has not been confirmed in humans.

P-DSIP showed greater activity in one central administration rat sleep experiment, but its effects varied depending on the dose and the experimental model [16]. There is a lack of adequate direct clinical studies in humans demonstrating greater efficacy or safety.

Is DSIP an endogenous hormone?

DSIP-like immunoreactivity has been identified in several tissues and biological fluids, but its endogenous precursor, synthesis pathway, receptor and biological identity remain incompletely understood.

Therefore, referring to DSIP as a fully characterised human hormone would go beyond the available evidence [2–4].

Disclaimer

The content is strictly for educational and scientific-information purposes. It does not constitute medical advice, a diagnosis, treatment or dosage recommendations, or a recommendation for the use of DSIP.

Delta sleep-inducing peptide (DSIP, emideltide) and phospho-DSIP are not approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), or the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of insomnia, lowering cortisol levels, the treatment of stress, or any other uses discussed in this article.

Available data are limited and come primarily from animal, ex vivo, in vitro, mechanistic studies, and small historical human studies. The article does not contain dosing, reconstitution, injection, or self-administration protocols.

References

[1] Schoenenberger, G. A., Maier, P. F., Tobler, H. J., Wilson, K., & Monnier, M. (1978). The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide. Pflügers Archiv, 376(2), 119–129. https://doi.org/10.1007/BF00581575

[2] Kovalzon, V. M., & Strekalova, T. V. (2006). Delta sleep-inducing peptide (DSIP): A still unresolved riddle. Journal of Neurochemistry, 97(2), 303–309. https://doi.org/10.1111/j.1471-4159.2006.03693.x

[3] Schoenenberger, G. A. (1984). Characterisation, properties and multivariate functions of delta-sleep-inducing peptide (DSIP). European Neurology, 23(5), 321–345. https://doi.org/10.1159/000115711

[4] Graf, M. V., & Kastin, A. J. (1986). Delta sleep-inducing peptide (DSIP): An update. Peptides, 7(6), 1165–1187. https://doi.org/10.1016/0196-9781(86)90148-8

[5] Huang, J. T., & Lajtha, A. (1978). The degradation of a nonapeptide, sleep inducing peptide, in rat brain: Comparison with enkephalin breakdown. Research Communications in Chemical Pathology and Pharmacology, 19(2), 191–199. https://pubmed.ncbi.nlm.nih.gov/25463/

[6] Grigoriev, V. V., Ivanova, T. A., Kustova, E. A., Petrova, L. N., Serkova, T. P., & Bachurin, S. O. (2006). Effects of delta sleep-inducing peptide on pre- and postsynaptic glutamate and postsynaptic GABA receptors in neurons of the cortex, hippocampus, and cerebellum in rats. Bulletin of Experimental Biology and Medicine, 142(4), 444–446. https://doi.org/10.1007/s10517-006-0323-9

[7] Umriukhin, P. E. (2002). Delta sleep-inducing peptide blocks excitatory effects of glutamate on rat brain neurones. Bulletin of Experimental Biology and Medicine, 134(1), 5–7. https://doi.org/10.1023/A:1020679815690

[8] Tsunashima, K., Kato, N., Masui, A., & Takahashi, K. (1994). The effect of delta sleep-inducing peptide (DSIP) on the changes of body (core) temperature induced by serotonergic agonists in rats. Peptides, 15(1), 61–65. https://doi.org/10.1016/0196-9781(94)90171-6

[9] Tsunashima, K., Masui, A., & Kato, N. (1990). The effect of delta sleep-inducing peptide (DSIP) and phosphorylated DSIP (P-DSIP) on the apomorphine-induced hypothermia in rats. Brain Research, 510(1), 171–174. https://doi.org/10.1016/0006-8993(90)90748-Z

[10] Graf, M., Christen, H., & Schoenenberger, G. A. (1982). DSIP/DSIP-P and circadian motor activity of rats under continuous light. Peptides, 3(6), 1053–1057. https://doi.org/10.1016/0196-9781(82)90161-9

[11] Chiodera, P., Volpi, R., Capretti, L., Giacalone, G., Caffarri, G., Davoli, C., Nigro, E., & Coiro, V. (1994). Different effects of delta-sleep-inducing peptide on arginine-vasopressin and ACTH secretion in normal men. Hormone Research, 42(6), 267–272. https://doi.org/10.1159/000184207

[12] Lesch, K. P., Widerlöv, E., Ekman, R., Laux, G., Schulte, H. M., Pfüller, H., & Beckmann, H. (1988). Delta sleep-inducing peptide response to human corticotropin-releasing hormone (CRH) in major depressive disorder: Comparison with CRH-induced corticotropin and cortisol secretion. Biological Psychiatry, 24(2), 162–172. https://doi.org/10.1016/0006-3223(88)90271-5

[13] Iukhananov, R. Iu., Rozhanets, V. V., Mikhaleva, I. I., & Maĭskiĭ, A. I. (1990). Analysis of the mechanism of the stress-protective action of delta sleep-inducing peptide. Bulletin of Experimental Biology and Medicine, 109(1), 46–47. https://pubmed.ncbi.nlm.nih.gov/2159352/

[14] National Center for Biotechnology Information. (2026). PubChem Compound Summary for CID 68816, Delta Sleep-Inducing Peptide. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/68816

[15] Mendzheritskii, A. M., Lysenko, A. V., Uskova, N. I., & Mikhaleva, I. I. (1997). Studies of the mechanism of the anticonvulsant effect of delta-sleep-inducing peptide in conditions of increased oxygen tension. Neuroscience and Behavioral Physiology, 27, 329–333. https://doi.org/10.1007/BF02461934

[16] Kimura, M., & Inoué, S. (1989). The phosphorylated analogue of DSIP enhances slow wave sleep and paradoxical sleep in unrestrained rats. Psychopharmacology, 97(1), 35–39. https://doi.org/10.1007/BF00443409

[17] Nakagaki, K., Ebihara, S., Usui, S., Honda, Y., & Takahashi, Y. (1988). Sleep-promoting effect following intracerebroventricular injection of a phosphorylated analogue of delta sleep-inducing peptide (DSIP-P) in rats. Neuroscience Letters, 91(2), 160–164. https://doi.org/10.1016/0304-3940(88)90761-6

[18] Graf, M. V., Saegesser, B., & Schoenenberger, G. A. (1987). Degradation and aggregation of delta sleep-inducing peptide (DSIP) and two analogs in plasma and serum. Peptides, 8(4), 599–603. https://doi.org/10.1016/0196-9781(87)90031-3

[19] Nakamura, A., & Shiomi, H. (1991). Phosphorylation of delta sleep-inducing peptide (DSIP) by casein kinase II in vitro. Peptides, 12(6), 1375–1377. https://doi.org/10.1016/0196-9781(91)90222-B